MarketWatch.com - MarketPulse
TEL AVIV (MarketWatch) -- Neurogesx Inc., the San Mateo, Calif., biotech company focused on pain-management therapies, agreed to privately place $25 million of stock and warrants. A group of institutional investors agreed to buy more than 4 million shares at $6.18 each, the company said in a statement on Wednesday. And the investors also received five-year warrants to buy more than 1.2 million more Neurogesx shares at an exercise price of $8.034 each. Neurogesx shares closed Monday at $6.04. Pacific Growth Equities placed the shares.